Project Grant R01DA061771
Award Date
9/1/24
Completion Date
7/31/29
Dollars Obligated
$773K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Jupiter, FL 33458, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), totaling $945,966 over the period of September 30, 2024 to July 31, 2029, will support research to unravel the neurobiological mechanisms by which the neuropeptide PEN and its receptor GPR83 interact with the mu-opioid receptor (MOR) in the periaqueductal gray (PAG) region of the brain. The goal is to determine if targeting the PEN-GPR83 pathway...
This Project Grant award of $373,181 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research focused on understanding the role of cholinergic interneurons in the ventral tegmental area that express mu-opioid receptors and their contribution to opioid reward, consumption, and withdrawal behaviors. The project aims to determine whether these interneurons and their mu-opioid receptors participate in opioid-related...
This federal Project Grant award of $1,213,117 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The objective is to develop novel chemical probes targeting the sodium binding site of the mu opioid receptor (MOR) to achieve functional selectivity and therapeutic benefits. The primary products/services include: Synthesis and pharmacological characterization of bitopic ligands that engage both the orthosteric and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $666,569 to the University of Florida to conduct research on the role of the ELFN1 cell-adhesion molecule in modulating glutamatergic signaling and synaptic plasticity in the nucleus accumbens, and how this impacts the rewarding effects of opioids. The 5-year project, running from August 1, 2024 to May 31, 2029, will employ behavioral, genetic,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to establish OPRM1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management. The $2,902,673 award, spanning September 2024 to May 2029, supports research at Rutgers, The State University of New Jersey, to characterize antisense oligonucleotides...
This Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is providing $147,656.00 to Emory University to examine the modulatory role of galanin in opioid reward. The project, running from February 1, 2025 to August 31, 2027, will leverage Emory University's expertise in biomedical research, neuroscience, and addiction studies to advance scientific understanding of the neurobiological mechanisms underlying...
This $148,568 Project Grant awarded by the National Institute on Drug Abuse (NIDA) through the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the molecular organization and signaling dynamics of GABABR-GIRK pathways. The project, conducted by the University of Florida, aims to define the functional signalosome and protein-protein binding interfaces within the GABABR-GIRK signaling complex. It will examine how these interactions change from the inactive to...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $421,200 to Oregon Health & Science University (OHSU) to develop new chemical biology tools to study the role of cannabinoid receptors in opioid use disorder. The key objectives are to expand OHSU's existing toolkit of fluorescent cannabinoid receptor probes and photoswitches to include the less-studied GPR55 receptor, and then apply these...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $284,040 to The Lieber Institute for Brain Development to conduct research on the molecular and circuit-level changes in the habenula brain region associated with opioid exposure. The study aims to generate a spatially-resolved atlas of opioid-induced gene expression changes in the rodent habenula at the cellular and circuit level, and to...
This $601,612 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the role of the habenula-interpeduncular nucleus (IPN) circuit in the development of opioid tolerance and withdrawal. The project will use viral approaches, ribosome profiling, and calcium imaging in mice to examine gene expression changes and neuronal activity in the IPN in response to chronic oxycodone exposure. The...